Background-Melanoma is the most common malignancy encountered during pregnancy. Conflicting data have led to ongoing confusion regarding pregnancy associated melanoma (PAM) in the media and among the public. The objective of this study was to better characterize both the clinical presentation of PAM and its prognostic implications.
Introduction
Melanoma is the most common malignancy encountered during pregnancy, accounting for 31% of all malignancies in the intrapartum period. (1, 2) For many years, pregnancy has been thought to have an adverse effect on the course of melanoma. Reports beginning in the 1950s suggested pregnancy increased the risk of melanoma development, metastasis and recurrence. (3) (4) (5) (6) Many hypotheses since then have been formulated, linking worsened outcomes to hyperpigmentation, relative immunosuppression, and hormone binding of melanocytes. (7) (8) (9) (10) Given the overall increase in melanoma incidence in women of childbearing age in the US, this topic has become even more pertinent. (11, 12) Editorials, systemic reviews, and media coverage of PAM persist but fail to draw definitive conclusions despite many years of attention and underpowered studies. (13) (14) (15) (16) (17) (18) (19) (20) (21) Many of the adequately powered studies that do exist come from large, non-US based registries, with a resultant lack of granular detail and reliability. (22) (23) (24) (25) The primary objective of this study was to query our large, single institution melanoma database to better characterize PAM with particular attention to overall survival (OS) and melanoma specific survival (MSS). Secondarily, we examined other clinical factors with regard to melanoma mortality and such as parity and gravidity, in addition to known prognostic factors such as age, stage, histologic type, Breslow thickness, and ulceration.
Methods
Female patients of reproductive age with American Joint Committee on Cancer (AJCC) stage 0-IV cutaneous melanoma were identified from the prospectively maintained John Wayne Cancer Institute melanoma database between January 1971 and May 2016. All patient data were de-identified, and this study was independently confirmed to be exempt from Institutional Review Board review. Melanomas were staged by seventh edition AJCC criteria. (26) (27) (28) In order to ensure adequate staging, patients without lymph node staging for melanomas with Breslow thickness ≥0.75 mm were excluded from analysis (n=540 non-PAM, n=43 PAM). Pregnancy associated melanoma is a field derived either from patient questionnaire responses (self reported) or direct physician queries (physician reported). The JWCI melanoma database defines PAMs by an affirmative response to "did melanoma develop during pregnancy." This includes cases that developed de novo during pregnancy or melanomas that arose from pre-existing lesions that changed during pregnancy. We cannot exclude the possibility that some of these lesions were identified incidentally during prenatal visits. Laboratory pregnancy confirmation is incomplete in this data set as patients receiving office based excisions would not have routinely received urine or serum pregnancy evaluations. For this reason, we are not able to comment on the women who were deemed pregnant based on preoperative bHCG alone. Clinical and histopathologic factors were examined between PAM and non-PAM groups. T-test was used to analyze age at diagnosis, parity, gravidity, and Breslow thickness. Chi-square test was used for Clark level, anatomic site, ulceration, sentinel lymph node examination status, recurrence status, type of first recurrence, stage at diagnosis, and stage first seen at JWCI. A 1:1 matched pair sample was then created using pairs of PAM and non-PAM patients who were matched for Breslow thickness, age, stage and ulceration status. With respect to age, we matched utilizing the following categories: <25, 25 -=35, ≥3. With respect to Breslow thickness, we matched for categories: ≤ 0.75, 0.75 -<2.00, 2.00 -≤4.00, > 4.00 and unknown. For stage at diagnosis, we matched using categories: 0, I/II, and III. Finally, for ulceration, we matched using categories: yes, no and unknown. These details have been incorporated in to the manuscript on page 4. Univariable and then multivariable analyses were conducted with the matched data to analyze DFS, OS and MSS for patients with stage 0/I/II and stage III cutaneous melanoma at diagnosis. Due to the paucity of PAM patients with Stage IV disease at diagnosis (n=1), those patients were excluded from this analysis. Kaplan-Meier survival curves were then plotted for OS and MSS and compared using the log-rank test. SAS software, version 9.3 (SAS Institute) was used for all analyses. A two-sided p-value of 0.05 or lower was considered to indicate statistical significance.
Results
Of the entire patient cohort (n=2025), 156 women (7.7%) with PAM were identified after selection criteria applied. No cases of transplacental transfer of melanoma were identified. Clinical presentation of melanoma was similar for PAM and non-PAM patients with no significant differences in Breslow thickness (1.30 mm vs. 1.34 mm, p=0.737), histologic type, or primary tumor site (see Table 1 ). Age was greater in the non-PAM patients (36.8 vs 31.7 years, p<0.001). There was also no significant difference in stage at diagnosis. (Table 1 ) Parity was significantly increased in the PAM group, p=0.010, as was gravidity, p<0.001 At 10-years; disease-free survival was 65.7% and 62.3% for the non-PAM and PAM groups, respectively (p=0.8934). Mean disease-free survival was also similar at 24.48 years in the non-PAM group and 20.65 years in the PAM group.
Matched Pair Sample
In an attempt to decrease potential biases associated with delay in diagnosis of PAMs, we created a matched pair sample. Each PAM patient was matched with a non-PAM patient by Breslow thickness, age, stage and ulceration status. In this group of 310 patients (155 matched pairs), PAMs had a median follow-up of 14.6 years (range 0-42.6 years), and nonPAMs had a median follow-up of 11.1 years (0 -48.5 years). When comparing the PAM and non-PAM matched pairs, clinical features were similar (see Table 2 ) except for histologic type (p=0.046), primary site (p=0.040), gravidity and parity (p<0.001, p<0.001). There were also no differences in recurrence between the PAM and non-PAM group (Table 2) .
Univariable Survival Analysis by Stage
For matched patients with stage 0/I/II melanoma at diagnosis, there were no differences identified in DFS (p=0.880, HR 0.97, 95% CI 0.62-1.5), OS (p=0.219, HR 0.73, 95% CI 0.44-1.21) or MSS (p=0.670, HR 0.89, 95% CI 0.51-1.53) for PAMs. For those patients with stage III melanoma at diagnosis, there were no differences in DFS (p=0.858, HR 0.94, 95% CI 0.46-1.93) OS (p=0.365, HR 0.64 95% CI 0.24-1.69) or MSS (p=0.595, HR 0.75, 95% CI 0.26-2.17) for PAMs. Concordant results were obtained when Kaplan-Meier curves were plotted and compared using log-rank test for OS and MSS for both stage 0/I/II at diagnosis ( Figure 1 ) and stage III at diagnosis (data not shown).
Expected differences in DFS, OS and MSS with regard to increasing Breslow thickness, stage first seen, ulceration, Clark level, histologic type and recurrence data (Tables 3-5) were identified for patients with stage 0/I/II melanoma at diagnosis. For patients with stage III melanoma at diagnosis, none of the clinicopathologic factors assessed were significantly associated with significant DFS, OS or MSS differences except for ulceration.
Univariable Reproductive History and Survival Differences
Interestingly, increasing gravidity was associated with worse DFS (p=0.026, HR 1.18, 95% CI 1.02-1.36), OS (p=0.042 HR 1.19 95% CI 1.01-1.40) and MSS (p=0.034, HR 1.21 95% CI 1.02-1.44) for stage 0/I/II melanomas, but these differences were not seen for stage III patients. Conversely, when parity was examined, there were no significant differences in DFS (p=0.330, HR 1.07, 95% CI 0.93-1.24), OS (p=0.562, HR 1.05 95% CI 0.88-1.26) or MSS (p=0.556 HR 1.06 95% CI 0.88-1.28) for stage 0/I/II melanomas. There were also no significant differences in OS or MSS for stage III patients with respect to parity as an independent prognostic factor.
Multivariable Survival Analysis by Stage
For patients with stage 0/I/II or stage III melanoma at diagnosis, there were no significant differences identified in DFS, OS or MSS for PAMs in the model (Tables 3-5 , not shown). The only factors associated with significant differences in OS were ulceration (yes or unknown) and increasing Breslow thickness for stage 0/I/II melanoma. (Table 3 Table 5 ) There were no factors associated with significant differences in Stage III patients with respect to DFS, OS and MSS on multivariable analysis.
Discussion
Despite previous study, controversy remains for women of childbearing age at risk for or diagnosed with cutaneous melanoma. In our institutional analysis, the incidence of PAM was 7.7%, congruent with previous work from this institution identifying a 8.7 percent incidence of PAM. (29) In early 2016, Tellez and colleagues reported that women with melanoma arising during or within one year of childbirth had a significantly worse prognosis when compared to their non-pregnant counterparts. (30) This study was limited by its small, retrospective nature; additionally, only 19 of 41 patients in the study had melanoma diagnosed during pregnancy. Based on multivariable analysis of this limited sample, the authors reported a 9-fold increase in recurrence (odds ratio (OR) 9.30, p=0.01), a 7-fold increase in metastasis (OR 6.70, p=0.01) and a 5-fold increase in mortality (OR 5.10, p=0.03). was greater in women who were diagnosed while pregnant (p=0.002), however once Breslow thickness was controlled for, survival rates did not differ (p=0.1). (32) To our knowledge, this is the first study associating increased gravidity to worsened survival outcomes in women of childbearing age with stage 0/I/II melanoma. Mechanisms underlying this finding could be associated with hormonal differences or other uncharacterized risk factors associated with gravidity. Future study will be needed to fully examine this association in a prospective manner. Also of note, while we do not have consistent or reliably documented follow up for babies born to these mothers with PAM, no cases of transplacental melanoma have been identified in the JWCI melanoma database comprising approximately 15,600 patients to date. Compared to larger registry-based studies, our data comes from a well-maintained and reliable single institution database with extensive follow up. Additionally, we excluded patients with melanomas ≥ 0.75 mm thick who did not receive nodal staging, thereby limiting non-standard care and inaccurately staged lesions. In contrast to previous studies that were not matched for pertinent factors such as Breslow thickness, age, and stage; our study was not clouded by these known prognostic factors.
Limitations of this study include its retrospective nature and treatment-related biases inherent to our referral center. Additionally, the majority of patients evaluated exhibited favorable prognostic factors and few PAMs had stage III disease or thick primary tumors (n=17 and n=5 respectively). Finally, due to the time period over which this data was collected, some subjects did not have complete data with regard to histology, ulceration and lymph node staging exam, which introduces some amount of uncertainty with regards to their initial prognosis. Despite these limitations, we believe this work accurately reflects PAM incidence and outcomes.
Conclusions
This, the largest, single-institution study examining the characteristics and outcomes associated with melanoma arising during pregnancy demonstrates no significant difference in DFS, OS or MSS. Pregnant patients should be screened for melanoma in a similar manner to non-pregnant patients and should be counseled that their prognosis is not adversely affected by pregnancy. PAM, pregnancy associated melanoma; ALM, acral lentiginous melanoma; LMM, lentigo maligna melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma
